Abstract: A structural flame retardant high strength low exothermic polymer grouting material for consolidating, belonging to a technical field of polyurethane material, is produced by combined the polyether polyol and the modified isocyanate in a weight ratio of 100:(100-160), leading to internal reaction temperature ?100° C., strength ?60 mPa, bonding ?3 mPa, oxygen index ?28% while no halogen and no effect on water quality, odor level (80° C.) ?3.5, and fog test ?5 mg (which means no physical additive flame retardant is diffused into the environment). In particular, with no halogen, which is known as environmental hormones, in the plasticizers, there will be less combustion smoke, wherein the present invention will not release corrosive or irritating hydrogen halide gas, nor produce toxic carcinogens polybrominated benzoxins and polybrominated dibenzofurans, thereby avoiding the long-term impact of the material on the environment.

Abstract: The present disclosure provides for recombinant oncolytic viruses with gene deletions or insertions which result in downregulation of Major Histocompatibility Complex class I and alternatively or additively upregulation of Major Histocompatibility Complex class II. Immunologic and pharmaceutical compositions comprising these recombinant viruses and methods of using these compositions are also presented.

Abstract: The present disclosure provides for recombinant oncolytic viruses with gene deletions or insertions which result in downregulation of Major Histocompatibility Complex class I and alternatively or additively upregulation of Major Histocompatibility Complex class II. Immunologic and pharmaceutical compositions comprising these recombinant viruses and methods of using these compositions are also presented.

Abstract: The present disclosure provides for recombinant oncolytic viruses with gene deletions or insertions which result in downregulation of Major Histocompatibility Complex class I and alternatively or additively upregulation of Major Histocompatibility Complex class II. Immunologic and pharmaceutical compositions comprising these recombinant viruses and methods of using these compositions are also presented.

Abstract: The disclosure relates to modified oncolytic viruses. The modified oncolytic viruses of the disclosure comprise modification in the viral genome encoding exogenous nucleic acids to enhance the oncolytic immunotherapy by remodeling the tumor microenvironment and with enhanced systemic delivery. The disclosure further relates to compositions comprising the modified oncolytic viruses, kits containing the same, and methods of using the oncolytic viruses.

Abstract: A model management system adaptively refines a training dataset for more effective visual inspection. The system trains a machine learning model using the initial training dataset and sends the trained model to a client for deployment. The deployment process generates outputs that are sent back to the system. The system determines that performance of predictions for noisy data points are inadequate and determines a cause of failure based on a mapping of the noisy data point to a distribution generated for the training dataset across multiple dimensions. The system determines a cause of failure based on an attribute of the noisy datapoint that deviates from the distribution of the training dataset and performs refinement towards the training dataset based on the identified cause of failure. The system retrains the machine learning model with the refined training dataset and sends the retrained machine learning model back to the client for re-deployment.

Abstract: This disclosure provides a modified oncolytic virus that can contain modifications in the viral genome and exogenous nucleic acids coding for proteins. The modified oncolytic virus can be utilized as a platform vector for systemic delivery.

Abstract: This disclosure provides a modified oncolytic virus that can contain modifications in the viral genome and exogenous nucleic acids coding for proteins. The modified oncolytic virus can be utilized as a platform vector for systemic delivery.

Abstract: This disclosure provides a modified oncolytic poxvirus, such as a vaccinia virus, that can contain modifications in the viral genome that increases production of an extracellular enveloped form of the virus. The modified oncolytic poxvirus can be utilized as a vector for systemic delivery. Also provided are methods of using the modified oncolytic poxvirus.

Abstract: This disclosure provides a modified oncolytic virus that can contain modifications in the viral genome and exogenous nucleic acids coding for proteins. The modified oncolytic virus can be utilized as a platform vector for systemic delivery.

Abstract: Provided herein are methods of manufacturing viruses. Also provided herein are bioreactors comprising virus-infected host cells comprising viruses. In some aspects, the present disclosure relates to production of recombinant oncolytic viruses, e.g., recombinant vaccinia viruses.

Abstract: This disclosure provides a modified oncolytic virus that can contain modifications in the viral genome and exogenous nucleic acids coding for proteins. The modified oncolytic virus can be utilized as a platform vector for systemic delivery.

Abstract: This disclosure provides a modified oncolytic virus that can contain modifications in the viral genome and exogenous nucleic acids coding for proteins. The modified oncolytic virus can be utilized as a platform vector for systemic delivery.

Abstract: Tissue slices and whole organisms offer substantial challenges to fluorescence imaging. Autofluorescence and absorption via intrinsic chromophores, such as flavins, melanin, and hemoglobins, confound and degrade output from all fluorescent tags. An “optical window,” farther red than most autofluorescence sources and in a region of low hemoglobin and water absorbance, lies between 650 and 900 nm. This valley of relative optical clarity is an attractive target for fluorescence-based studies within tissues, intact organs, and living organisms. Novel fluorescent tags were developed herein, based upon a genetically targeted fluorogen activating protein and cognate fluorogenic dye that yields emission with a peak at 733 nm exclusively when complexed as a “fluoromodule”. This tool improves substantially over previously described far-red/NIR fluorescent proteins in terms of brightness, wavelength, and flexibility by leveraging the flexibility of synthetic chemistry to produce novel chromophores.

Abstract: Tissue slices and whole organisms offer substantial challenges to fluorescence imaging. Autofluorescence and absorption via intrinsic chromophores, such as flavins, melanin, and hemoglobins, confound and degrade output from all fluorescent tags. An “optical window,” farther red than most autofluorescence sources and in a region of low hemoglobin and water absorbance, lies between 650 and 900 nm. This valley of relative optical clarity is an attractive target for fluorescence-based studies within tissues, intact organs, and living organisms. Novel fluorescent tags were developed herein, based upon a genetically targeted fluorogen activating protein and cognate fluorogenic dye that yields emission with a peak at 733 nm exclusively when complexed as a “fluoromodule”. This tool improves substantially over previously described far-red/NIR fluorescent proteins in terms of brightness, wavelength, and flexibility by leveraging the flexibility of synthetic chemistry to produce novel chromophores.